Lyell Immunopharma, Inc.
LYELNasdaqCIK 1806952HealthcareFiscal year ends Dec 31
Reports and events: 86 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1020:13 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-387890 |
| 2026-08-0620:27 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-054367 |
| 2026-08-0620:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-054330 |
| 2026-06-1520:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-271071 |
| 2026-05-0620:14 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-031284 |
| 2026-05-0620:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031269 |
| 2026-04-2420:05 ET | DEF 14A | Proxy statementPeriod 2026-06-10 | 0001140361-26-016686 |
| 2026-03-1220:16 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-017253 |
| 2026-03-1220:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-017244 |
| 2026-03-0912:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-097615 |
| 2025-12-0811:02 ET | 8-K | 8.01 Other events | 0001193125-25-310469 |
| 2025-12-0521:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-309621 |
| 2025-11-1221:20 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001628280-25-051619 |
| 2025-11-1221:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-051603 |
| 2025-11-1012:32 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-273269 |
| 2025-11-0313:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-261753 |
| 2025-09-1620:22 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-205020 |
| 2025-08-1220:13 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001806952-25-000008 |
| 2025-08-1220:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001806952-25-000007 |
| 2025-07-2512:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-164853 |
| 2025-06-2620:07 ET | 8-K | 3.02 Unregistered sale of equity | 0001193125-25-148897 |
| 2025-06-1712:49 ET | 8-K | 8.01 Other events | 0001193125-25-141795 |
| 2025-06-0920:23 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-137853 |
| 2025-05-2820:00 ET | 8-K | 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001193125-25-129448 |
| 2025-05-2120:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-123970 |
| 2025-05-1320:41 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-025135 |
| 2025-05-1320:39 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-025128 |
| 2025-04-2120:05 ET | DEF 14A | Proxy statementPeriod 2025-05-15 | 0001140361-25-014721 |
| 2025-04-0121:01 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001193125-25-070521 |
| 2025-03-1120:13 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-011978 |
| 2025-03-1120:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-011960 |
| 2025-01-2421:39 ET | 8-K | 3.01 Delisting notice | 0001193125-25-012249 |
| 2025-01-1014:10 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001628280-25-001065 |
| 2024-12-1002:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-273688 |
| 2024-11-2621:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-266101 |
| 2024-11-0721:16 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-046285 |
| 2024-11-0721:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-046254 |
| 2024-10-3120:45 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-248760 |
| 2024-10-2420:06 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-242808 |
| 2024-08-0720:10 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-035617 |
| 2024-08-0720:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-035603 |
| 2024-06-2612:32 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-168597 |
| 2024-06-1420:07 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-161601 |
| 2024-05-0612:06 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-020467 |
| 2024-05-0612:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-020466 |
| 2024-04-2220:15 ET | DEF 14A | Proxy statementPeriod 2023-06-14 | 0001140361-24-021008 |
| 2024-02-2821:13 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001628280-24-007592 |
| 2024-02-2821:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-007579 |
| 2023-11-2021:26 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-280680 |
| 2023-11-0721:14 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001628280-23-037360 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.